Products with Hepatoprotective bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4304 | Kaerophyllin |
| 1. Kaerophyllin can protect the rat liver from TAA-caused injury and fibrogenesis by suppressing hepatic inflammation and inhibiting HSC activation, possibly through upregulation of PPAR-γ expression. 2. Kaerophyllin inhibits AB-induced LX-2 activation and migration with downregulation of Akt/ERK phosphorylations and NF-κB activity. | |
| BCN4320 | Cleomiscosin A |
| 1. Cleomiscosin A and brusatol are antitumor agents, have antileukemic principles. 2. Cleomiscosin A has antioxidant activity, it could be beneficial in preventing LDL oxidation in atherosclerotic lesions. 3. Cleomiscosin A methyl ether derivatives have anti-inflammatory activity. 4. Cleomiscosin A shows inhibitory activity to TNF-α secretion of the mouse peritoneal macrophages. 5. The mixture of three compounds (cleomiscosin A, B and C) is showing the significant protective effects against CCl(4)-induced hepatotoxicity in small animals and also coumarinolignoids are well tolerated by small animals in acute oral study. | |
| BCN4385 | Rutaecarpine |
| Rutaecarpine is an inhibitor of COX-2 with an IC50 value of 0.28 μM, and is also a potent inhibitor of CYP1A2. Rutaecarpine has anti-atherosclerosis, immunosuppressive, anti-inflammatory, gastroprotective, vasorelaxing, antihypertensive and anti-platelet effects. Rutaecarpine has positive inotropic and chronotropic effects on the guinea-pig isolated right atria, possible involvement of vanilloid receptors. Rutaecarpine may be useful in the prevention of ultraviolet A-induced photoaging, it inhibits ultraviolet A-induced reactive oxygen species generation, resulting in the enhanced expression of matrix metalloproteinase (MMP)-2 and MMP-9 in human skin cells. | |
| BCN4388 | Cleomiscosin C |
| 1. Cleomiscosin C has antioxidant activity, it protects against the oxidative modification of apoB-100 induced by either Cu2+ or HOCl ( IC50s of 23.6 and 3.9 microM, respectively), suggests that it could be beneficial in preventing LDL oxidation in atherosclerotic lesions. 2. Cleomiscosins A, B and C exhibit liver-protective properties. | |
| BCN4534 | Limonexic acid |
| 1. Limonexic acid shows antinociceptive actions , it produces dose-related inhibition of glutamate- and capsaicin-induced pain. 2. Limonexic acid can effectively protect hepatocyte against CCl4-induced injury. | |
